You are viewing the site in preview mode

Skip to main content

Advertisement

Table 2 Patient characteristics: table below summarizes the individual patient characteristics

From: Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma

Patient Age at start of P (y) Stage at diagn-osis Prior treatment before KI PD-L1 status KI Time on KI alone (m) Time on KI + P (m) Change in target lesions and BOR on KI + P PFS On KI + P (m) OS from KI (m) OS from KI+P (m) Alive (A)/Deceased (D)
1 56 IVC BC, CXRT 5% DT 4.3 3.1 32% PD 0.7 7.4 3.1 D
2 68 IVC BC 30% DT 9.6 3.8 21% PD 1.5 13.4 3.8 D
3 57 IVB Sg, CXRT 80% L 1.9 6.9 19% PD 1.5 8.9 6.9 D
4 58 IVC Sg, CXRT 5% DT 26.2 13.9 −7% SD 0.6 40.1 13.9 A
5 60 IVC BC 50% L 5.5 15.8 −8% SD 12.8 21.4 15.8 A
6 47 IVB Sg, CXRT 60% DT 2.4 3 −14% SD 3 5.4 3 D
7 69 IVC CXRT n/A DT 2 4.1 −19% SD 3.1 6.2 4.1 D
8 60 IVC SC, BC > 95% DT 1.2 6.2 −35% PR 6.2 7.4 6.2 A
9 84 IVC Sg-Lobectomy > 10% L 2.1 8.3 −45% PR 8.3 10.4 8.3 D
10 57 IVC SC, XRT n/A L 2.4 16.1 −47% PR 13.1 18.5 16.1 A
11 73 IVC Sg, RAI 20% T 3.7 4.9 −48% PR 2.6 6.7 4.9 A
12 76 IVB Sg, RAI > 90% L 1.5 5 −69% PR 5 5.8 5 D
  1. Sg Surgery, CXRT Chemoradiation, BC Bridging chemotherapy with paclitaxel with or without carboplatin while awaiting KI, SC Systemic cytotoxic chemotherapy, XRT external beam radiation, RAI radioactive iodine, DT dabrafenib+trametinib, L lenvatinib, T trametinib alone, w weeks, m months, y years, KI kinase inhibitor, BOR best overall response, PFS progression-free survival, OS overall survival, PD progressive disease, SD stable disease, PR, partial response